94 related articles for article (PubMed ID: 21332025)
1. Estrogens modulate RANKL-RANK/osteoprotegerin mediated interleukin-6 effect on thyrotoxicosis-related bone turnover in mice.
Mysliwiec J; Zbucki R; Nikolajuk A; Mysliwiec P; Kaminski K; Bondyra Z; Dadan J; Gorska M; Winnicka MM
Horm Metab Res; 2011 Apr; 43(4):236-40. PubMed ID: 21332025
[TBL] [Abstract][Full Text] [Related]
2. Role of interleukin-6 on RANKL-RANK/osteoprotegerin system in hypothyroid ovariectomized mice.
Mysliwiec J; Zbucki R; Nikolajuk A; Mysliwiec P; Taranta A; Kaminski K; Bondyra Z; Dadan J; Gorska M; Winnicka MM
Folia Histochem Cytobiol; 2010 Dec; 48(4):549-54. PubMed ID: 21478097
[TBL] [Abstract][Full Text] [Related]
3. A crucial role of interleukin-6 in the pathogenesis of thyrotoxicosis-related disturbances of bone turnover in mice.
Mysliwiec J; Zbucki R; Winnicka MM; Sawicki B; Nikolajuk A; Kaminski K; Mysliwiec P; Musial W; Bondyra Z; Walecki J; Gorska M
Horm Metab Res; 2007 Dec; 39(12):884-8. PubMed ID: 17973207
[TBL] [Abstract][Full Text] [Related]
4. Interleukin-6 is not essential for bone turnover in hypothyroid mice.
Mysliwiec J; Zbucki R; Winnicka M; Sawicki B; Nikolajuk A; Kaminski K; Mysliwiec P; Musial W; Bondyra Z; Walecki J; Gorska M
Folia Histochem Cytobiol; 2007; 45(4):387-92. PubMed ID: 18165179
[TBL] [Abstract][Full Text] [Related]
5. Biglycan deficiency interferes with ovariectomy-induced bone loss.
Nielsen KL; Allen MR; Bloomfield SA; Andersen TL; Chen XD; Poulsen HS; Young MF; Heegaard AM
J Bone Miner Res; 2003 Dec; 18(12):2152-8. PubMed ID: 14672350
[TBL] [Abstract][Full Text] [Related]
6. IL-1 plays an important role in the bone metabolism under physiological conditions.
Lee YM; Fujikado N; Manaka H; Yasuda H; Iwakura Y
Int Immunol; 2010 Oct; 22(10):805-16. PubMed ID: 20679512
[TBL] [Abstract][Full Text] [Related]
7. An acute injection of Porphyromonas gingivalis lipopolysaccharide modulates the OPG/RANKL system and interleukin-6 in an ovariectomized mouse model.
Lu HK; Yeh KC; Wu MF; Li CL; Tseng CC
Oral Microbiol Immunol; 2008 Jun; 23(3):220-5. PubMed ID: 18402608
[TBL] [Abstract][Full Text] [Related]
8. Expression profiles of receptor activator of nuclear factor kappaB ligand, receptor activator of nuclear factor kappaB, and osteoprotegerin messenger RNA in aged and ovariectomized rat bones.
Ikeda T; Utsuyama M; Hirokawa K
J Bone Miner Res; 2001 Aug; 16(8):1416-25. PubMed ID: 11499864
[TBL] [Abstract][Full Text] [Related]
9. Theoretical investigation of the role of the RANK-RANKL-OPG system in bone remodeling.
Pivonka P; Zimak J; Smith DW; Gardiner BS; Dunstan CR; Sims NA; Martin TJ; Mundy GR
J Theor Biol; 2010 Jan; 262(2):306-16. PubMed ID: 19782692
[TBL] [Abstract][Full Text] [Related]
10. Prostaglandin E2 induces expression of receptor activator of nuclear factor-kappa B ligand/osteoprotegrin ligand on pre-B cells: implications for accelerated osteoclastogenesis in estrogen deficiency.
Kanematsu M; Sato T; Takai H; Watanabe K; Ikeda K; Yamada Y
J Bone Miner Res; 2000 Jul; 15(7):1321-9. PubMed ID: 10893680
[TBL] [Abstract][Full Text] [Related]
11. Cytokine-controlled RANKL and osteoprotegerin expression by human and mouse synovial fibroblasts: fibroblast-mediated pathologic bone resorption.
Tunyogi-Csapo M; Kis-Toth K; Radacs M; Farkas B; Jacobs JJ; Finnegan A; Mikecz K; Glant TT
Arthritis Rheum; 2008 Aug; 58(8):2397-408. PubMed ID: 18668542
[TBL] [Abstract][Full Text] [Related]
12. Impaired bone resorption in cathepsin K-deficient mice is partially compensated for by enhanced osteoclastogenesis and increased expression of other proteases via an increased RANKL/OPG ratio.
Kiviranta R; Morko J; Alatalo SL; NicAmhlaoibh R; Risteli J; Laitala-Leinonen T; Vuorio E
Bone; 2005 Jan; 36(1):159-72. PubMed ID: 15664014
[TBL] [Abstract][Full Text] [Related]
13. Heparin enhances osteoclastic bone resorption by inhibiting osteoprotegerin activity.
Irie A; Takami M; Kubo H; Sekino-Suzuki N; Kasahara K; Sanai Y
Bone; 2007 Aug; 41(2):165-74. PubMed ID: 17560185
[TBL] [Abstract][Full Text] [Related]
14. Expression of RANKL and OPG correlates with age-related bone loss in male C57BL/6 mice.
Cao J; Venton L; Sakata T; Halloran BP
J Bone Miner Res; 2003 Feb; 18(2):270-7. PubMed ID: 12568404
[TBL] [Abstract][Full Text] [Related]
15. Prolactin directly enhances bone turnover by raising osteoblast-expressed receptor activator of nuclear factor kappaB ligand/osteoprotegerin ratio.
Seriwatanachai D; Thongchote K; Charoenphandhu N; Pandaranandaka J; Tudpor K; Teerapornpuntakit J; Suthiphongchai T; Krishnamra N
Bone; 2008 Mar; 42(3):535-46. PubMed ID: 18166509
[TBL] [Abstract][Full Text] [Related]
16. Circulating amounts of osteoprotegerin and RANK ligand: genetic influence and relationship with BMD assessed in female twins.
Abrahamsen B; Hjelmborg JV; Kostenuik P; Stilgren LS; Kyvik K; Adamu S; Brixen K; Langdahl BL
Bone; 2005 Apr; 36(4):727-35. PubMed ID: 15781001
[TBL] [Abstract][Full Text] [Related]
17. Changes in RANKL/OPG/RANK gene expression in peripheral mononuclear cells following treatment with estrogen or raloxifene.
Bashir A; Mak YT; Sankaralingam S; Cheung J; McGowan NW; Grigoriadis AE; Fogelman I; Hampson G
Steroids; 2005 Dec; 70(13):847-55. PubMed ID: 16005483
[TBL] [Abstract][Full Text] [Related]
18. Increased expression of IL-6 and RANK mRNA in human trabecular bone from fragility fracture of the femoral neck.
Tsangari H; Findlay DM; Kuliwaba JS; Atkins GJ; Fazzalari NL
Bone; 2004 Jul; 35(1):334-42. PubMed ID: 15207775
[TBL] [Abstract][Full Text] [Related]
19. The osteoprotegerin/RANK/RANKL system: a bone key to vascular disease.
D'Amelio P; Isaia G; Isaia GC
J Endocrinol Invest; 2009; 32(4 Suppl):6-9. PubMed ID: 19724159
[TBL] [Abstract][Full Text] [Related]
20. Osteoprotegerin/RANK/RANKL axis in cardiac remodeling due to immuno-inflammatory myocardial disease.
Liu W; Feng W; Wang F; Li W; Gao C; Zhou B; Ma M
Exp Mol Pathol; 2008 Jun; 84(3):213-7. PubMed ID: 18417124
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
